Successful first-in-human study exploiting a unique scalable Natural Killer-cell product
We report the first-in-human study exploiting a unique scalable NK-cell product generated ex vivo from CD34+ hematopoietic stem and progenitor cells (HSPC) from partially HLA-matched umbilical cord blood units.
Read more
PimBio vestigt zich op Pivot Park
Per 1 juni zijn de deuren van het kantoor van PimBio op Pivot Park geopend.
Read more
NTRC publishes target residence time-guided optimization of TTK inhibitors
This week, NTRC published results from its TTK (Mps1) drug discovery programme in the Journal of Molecular Biology.
Read more
Pluriomics BV partners with Pivot Park Screening Centre
Pluriomics partners with Pivot Park Screening Centre for Cardiovascular drug discovery services.
Read more
Synaffix Secures End-to-End Patent Protection of Its ADC Technology Platform as Its HydraSpace™ Patent Grants in the United States
Synaffix announced that a key patent covering its HydraSpace™ spacer technology has been granted by the US Patent and Trademark Office.
Read more
Lead Pharma Achieves Second Milestone for Development of Autoimmune Diseases Treatments in Sanofi Collaboration
Lead Pharma announced that it has achieved a second milestone under its research collaboration with Sanofi.
Read more
Rob Prins nieuwe voorzitter Raad van Bestuur Pivot Park
Rob Prins vervangt per 1 april Jan Pelle als voorzitter van de Raad van Bestuur van Pivot Park.
Read more
Enterprise System Partners and TraceLink Form Strategic Alliance
Enterprise System Partners announced it has established a strategic partnership with TraceLink.
Read more
New study in Oncotarget shows that stable aneuploid cells are more sensitive to TTK inhibition than chromosomally unstable cell lines
Stable aneuploid tumor cells are more sensitive to small molecule inhibitors of TTK than chromosome instable cells.
Read more